Loading…

Liquid chromatographic determination of unbound flecainide in therapeutic drug monitoring

An assay method was developed for determining unbound flecainide in serum by reversed phase-high performance liquid chromatography (HPLC). Serum water including unbound flecainide was separated by ultrafiltration of the serum sample and subjected to C 18-cartridge extraction followed by HPLC analysi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical and biomedical analysis 2003-06, Vol.32 (2), p.375-380
Main Authors: Katori, Kumi, Homma, Masato, Kuga, Keisuke, Yamaguchi, Iwao, Sugibayashi, Kenji, Kohda, Yukinao
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An assay method was developed for determining unbound flecainide in serum by reversed phase-high performance liquid chromatography (HPLC). Serum water including unbound flecainide was separated by ultrafiltration of the serum sample and subjected to C 18-cartridge extraction followed by HPLC analysis. The recovery of flecainide from serum water was greater than 93%. The coefficient variations for intra- and inter-day assay of flecainide were smaller than 2.4 and 3.7%, respectively. We applied the method to determining unbound flecainide in serum samples collected from 20 patients receiving oral flecainide (150–300 mg/day) for tachyarrhythmia. Total and unbound concentrations for serum flecainide were 403.5±200.8 ng/ml and 180.2±95.0 ng/ml, respectively. Linear relationship was observed between total and unbound concentrations ( r=0.978, P
ISSN:0731-7085
1873-264X
DOI:10.1016/S0731-7085(03)00130-4